You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
We are one of the only pharmaceutical companies in the world focused exclusively
on brain diseases and our speciality sets us apart. Our purpose is clear:
We are tirelessly dedicated to restoring brain health, so every person can be their best.
For more than 70 years, we’ve been pushing the boundaries of neuroscience. By
combining the logic of science with our passion for making a difference to
patients, we’ve pioneered some of the most important and commonly used
therapies within the antipsychotic and antidepressant markets.
We work closely with patients, healthcare professionals and the neuroscience
community to help uncover causes and to find potential new treatments that can
bring back quality of life to people living with brain diseases.
As a global specialist, we owe it to those who live with brain diseases to fight
stigma and promote improved treatment. That’s why we work to improve
understanding and parity of care across communities and societies – so we can
empower people and rebuild hope.
The Lundbeck Foundation is the majority owner of Lundbeck. Foundation ownership
allows us to stay focused on our areas of specialty. It also means that we are in a position to give back. With donations of approximately DKK 500 million a year to biomedical research, the Foundation supports the progress of health science.
Today, we’re 5,600 people in 50+ countries. We build on our Danish heritage, fostering a culture of collaboration and responsibility. Whether we work in labs or in
the field, we all have the same aim: to develop innovative treatments that improve the lives of people living with brain diseases. We call this Progress in Mind.
The mindset which governs our behavior in all we do.
We strive for Progress in Mind - our multifaceted approach to patients.
Lundbeck has developed some of the most widely prescribed therapies for brain diseases.
5,600 colleagues, 50+ countries, working with one aim.
UK-NOTPR-0499 | April 2022